Egetis appoints Karl Hård as Head of Investor Relations and Communication

Stockholm, Sweden, January 25, 2022 – Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced the appointment of Karl Hård, PhD, as Head of Investor Relations and Communication, effective February 1. Karl will be a member of the Company’s leadership team and report to the CEO Nicklas Westerholm.

Karl has over 25 years of experience in the global pharmaceutical industry having worked for almost 20 years at AstraZeneca and thereafter at biotechnology companies and a strategic communications consultancy firm. Prior to joining Egetis Karl was Head of Investor Relations at Redx Pharma in the UK, a precision medicines company listed on the London Stock Exchange. Before that he was at Optimum Strategic Communications, a leading healthcare communications firm in London, advising life science companies on investor relations and strategic communications. After leaving AstraZeneca in 2016 Karl joined Kiadis Pharma based in Amsterdam as Head of Investor Relations and Communication. Kiadis was listed on Euronext Amsterdam and Brussels but was subsequently acquired by Sanofi. Between 2007 and 2016 Karl held senior roles with increasing responsibilities in the Investor Relations function at AstraZeneca, latterly as Vice President IR.

Karl has been voted best IR professional in Europe in the Institutional Investor survey in the pharmaceutical sector. He brings valuable global IR connections to Egetis from long-standing relationships with leading investors and analysts.

In the 1990s Karl was Assistant Professor in Chemistry at Leiden University, The Netherlands, and he obtained a PhD in Chemistry from Utrecht University, The Netherlands. His scientific experience covers numerous fields, including endocrinology and rare diseases, and is backed by over 40 published scientific articles in peer-reviewed international journals.

Nicklas Westerholm, CEO Egetis, said: "We are excited to welcome Karl, a deeply experienced and respected investor relations professional to Egetis. His extensive experience and knowledge of investor relations, financial markets, business development, and medical science makes him ideal in the role of Head of Investor Relations at Egetis. Karl’s capital markets experience combined with his established global network will be invaluable as we continue to strengthen our investor and industry relationships with key stakeholders.”

About Egetis Therapeutics AB

Egetis Therapeutics is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious diseases with significant unmet medical needs in the orphan drug segment. The drug candidate Emcitate is developed as the first potential treatment for patients with MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. Triac Trial I (Phase IIb) and a long-term real-life study have been completed with clinically relevant and highly significant results on serum T3 concentrations and secondary clinical endpoints. Triac Trial II is an ongoing study in very young MCT8 deficiency patients (<30 months of age) investigating neurocognitive effects of early intervention with Emcitate. Results are expected in Q1 2024. Egetis intends to submit a marketing authorization application for Emcitate to the European Medicines Agency based on existing clinical data. Before submission for a New Drug Application in the US targeted in mid-2023, Egetis will conduct a randomized, placebo-controlled study in 16 treated patients to verify the results on T3 levels seen in previous clinical trials and publications. Emcitate holds Orphan Drug Designation (ODD) in the US and EU and has been granted Rare Pediatric Disease Designation and Fast Track Designation by the US FDA. The drug candidate Aladote is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote has been granted Orphan Drug Designation in the US and an application for ODD was submitted in Europe in Q1 2021. There is an ongoing dialogue with EMA on the appropriate indication for an ODD in the EU.
Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com